Drug stocks advance in early trading Monday, as shares of Human Genome Sciences leap on the release of more positive clinical data for its new lupus drug.

Among the companies whose shares are expected to see active trade in Monday’s session are the European banks as well as CIT, CNA, Dean Foods, Encore Acquisition, Ford, Humana, Loews, Nice, Terra and U.S. Bancorp.

No -- the chart below is not a misprint. Volatility is going through the roof in Human Genome Sciences (HGSI). It's binary event time next week as Steven Sears explains in the Striking Price:  On Wall Street traders use options which often cost about a handful of coins to wager on "binary" events.Human Genome Sciences is according to the JPMorgan analyst who follows the stock facing a "highly binary" event.Before European markets open Monday Human Genome Sciences and partner GlaxoSmithkine (GSK) are expected to report the much anticipated data from the second of two Phase 3 trials evaluating the ...

Drug stocks edged higher in early trading with shares of biotech groups BioMarin Pharmaceutical Inc. and Human Genome Sciences leading the pack.

Among the companies whose shares are expected to see active trade in Tuesday’s session are Apple, Boston Scientific, DuPont, GlaxoSmithKline, Human Genome Sciences, IMS Health, MPS, Novavax, New Oriental Education, Ford, Lexmark, TI and TJX.

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Benchmark Journal.